Structure Therapeutics insider tax-withholding sale reduces CTO stake to 118,704 shares

Rhea-AI Filing Summary

Ma Yingli, Chief Technology Officer and director of Structure Therapeutics Inc. (GPCR), reported a Form 4 showing a transaction on 07/01/2025. The filing discloses a disposition of 4,470 ordinary shares at a price of $6.8366 per share, leaving 118,704 ordinary shares beneficially owned following the transaction.

The Form 4 notes these shares were withheld by the issuer to satisfy income tax obligations related to the vesting of a restricted share unit award. The report was executed by an attorney-in-fact, Jun Yoon, and is part of routine insider reporting under Section 16.

Positive

• Disclosure complies with Section 16 reporting requirements, showing transparency
• Remaining ownership of 118,704 shares indicates continued insider stake following the tax-withholding event

Negative

• None.

Insights

Financial Analyst

TL;DR: A small, routine tax-withholding sale by an officer reduced holdings modestly; it appears non-material to company valuation.

The reported 4,470-share disposition at $6.8366 per share was performed to satisfy tax obligations from RSU vesting, per the filing. The remaining position of 118,704 ordinary shares suggests continued meaningful ownership by the CTO but the transaction size is limited relative to typical outstanding shares of a public company. There is no indication of trading for liquidity or change in control from the data provided.

Corporate Governance Expert

TL;DR: Disclosure meets Section 16 requirements; transaction labeled as tax withholding is consistent with compensation events.

The Form 4 correctly identifies the reporting person, role (CTO and director), transaction date, code F disposition, and an explanation that shares were withheld to satisfy income tax obligations tied to RSU vesting. The filing was signed via attorney-in-fact, which is an acceptable execution method. No governance or control issues are evident from the filing alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ma Yingli

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF TECHNOLOGY OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	07/01/2025		F		4,470(2)	D	$6.8366	118,704	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.

	/s/ Jun Yoon, Attorney-in-Fact	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Ma Yingli report on the Form 4 for GPCR?

The Form 4 reports a disposition of 4,470 ordinary shares on 07/01/2025 at $6.8366 per share, leaving 118,704 shares beneficially owned.

Why were shares disposed of according to the filing?

The filing explains the shares were withheld by the issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.

What role does the reporting person hold at Structure Therapeutics (GPCR)?

Ma Yingli is the Chief Technology Officer and a director of Structure Therapeutics Inc., as stated on the Form 4.

When was the transaction dated and who signed the Form 4?

The transaction date is 07/01/2025. The Form 4 was signed by Jun Yoon, Attorney-in-Fact on 08/20/2025.

What does transaction code 'F' indicate in this Form 4?

In this filing, transaction code F is used and the explanation states the shares were withheld for tax obligations related to RSU vesting.